Compare DK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | IDYA |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2017 | 2019 |
| Metric | DK | IDYA |
|---|---|---|
| Price | $52.44 | $37.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | $39.94 | ★ $52.86 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.67 | 61.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | N/A | $201.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $19.81 | $21.33 |
| 52 Week High | $54.17 | $39.28 |
| Indicator | DK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 71.16 |
| Support Level | $41.67 | $29.51 |
| Resistance Level | N/A | $38.17 |
| Average True Range (ATR) | 2.32 | 1.68 |
| MACD | 0.87 | 0.55 |
| Stochastic Oscillator | 88.29 | 93.98 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.